Research Article

Monitoring performance of progression assessment criteria for cancer antigen 125 among patients with ovarian cancer compared by computer simulation

*Author for correspondence:

E-mail Address: suher.othman.hussein.rashid.abu.hassaan@regionh.dk

Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark

Norwegian Quality Improvement Primary Care Laboratories (NOKLUS), Section for General Practice, University of Bergen, Bergen, Norway

Search for more papers by this author

Flemming Lund

Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author

Dorte L Nielsen

Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author

Malgorzata K Tuxen

Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author

György Sölétormos

Department of Clinical Biochemistry, North Zealand Hospital Hospital, University of Copenhagen, Copenhagen, Denmark

Search for more papers by this author

Published Online:6 Jul 2015https://doi.org/10.2217/bmm.15.47

View article

Abstract

Background: Cancer antigen 125 (CA125) is used to monitor tumor burden among patients with advanced serous epithelial ovarian cancer. The purpose is to compare the monitoring performance of seven previously proposed criteria. Materials & methods: The CA125 assessment criteria were applied to simulated datasets. We investigated the ability to provide information on CA125 increments as well as their robustness against false positive signals. Results: For baseline concentrations above cut-off, the best performing criterion was based on a confirmed increment ≥2.5-times the nadir concentration. For baseline concentrations below cut-off, the best performing criterion was based on a confirmed increment from ≤ cut-off to >two-times cut-off. Discussion: Computer simulation models may be useful for a preclinical validation of criteria to be investigated in clinical trials.

Keywords:

References

1 Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. Clin. Chim. Acta 415, 341–345 (2013).
Medline CASGoogle Scholar
2 Rustin GJ, Nelstrop A, Stilwell J et al. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur. J. Cancer 28(1), 79–82 (1992).
Medline CASGoogle Scholar
3 Rustin GJ. Tumour markers for ovarian cancer. Eur. J. Cancer 28(1), 2–3 (1992).
Medline CASGoogle Scholar
4 Rustin GJ, Nelstrop AE, Tuxen MK et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7(4), 361–364 (1996).
Medline CASGoogle Scholar
5 Rustin GJ, Marples M, Nelstrop AE et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J. Clin. Oncol. 19(20), 4054–4057 (2001).
Medline CASGoogle Scholar
6 Rustin GJ, Bast RC Jr, Kelloff GJ et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin. Cancer Res. 10(11), 3919–3926 (2004).
Medline CASGoogle Scholar
7 Rustin GJ, Quinn M, Thigpen T et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J. Natl Cancer Inst. 96(6), 487–488 (2004).
MedlineGoogle Scholar
8 Rustin GJ, Timmers P, Nelstrop A et al. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J. Clin. Oncol. 24(1), 45–51 (2006).
Medline CASGoogle Scholar
9 Rustin GJ, van der Burg ME, Griffin CL et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376(9747), 1155–1163 (2010).
MedlineGoogle Scholar
10 Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int. J. Gynecol. Cancer 21(2), 419–423 (2011).
MedlineGoogle Scholar
11 Rustin GJ. Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann. Oncol. 22(Suppl. 8), viii45–viii48 (2011).
MedlineGoogle Scholar
12 Tuxen MK, Sölétormos G, Dombernowsky P. Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy. Br. J. Cancer 84(10), 1301–1307 (2001).
Medline CASGoogle Scholar
13 Tuxen MK, Sölétormos G, Dombernowsky P. Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up. Scand. J. Clin. Lab. Invest. 62(3), 177–188 (2002).
Medline CASGoogle Scholar
14 Friedlander M, Trimble E, Tinker A et al. Clinical trials in recurrent ovarian cancer. Int. J. Gynecol. Cancer 21(4), 771–775 (2011).
MedlineGoogle Scholar
15 Sölétormos G, Petersen P H, Nielsen D. Computer-simulated tumor-marker data used to compare progression criteria for cytokeratin tissue polypeptide antigen in metastatic breast cancer. Clin. Chem. 47(11), 2035–2037 (2001).
Medline CASGoogle Scholar
16 Petersen PH, Sölétormos G, Pedersen MF et al. Interpretation of increments in serial tumour biomarker concentrations depends on the distance of the baseline concentration from the cut-off. Clin. Chem. Lab. Med. 49(2), 303–310 (2011).
Medline CASGoogle Scholar
17 Lund F, Petersen PH, Pedersen M F et al. Criteria to interpret cancer biomarker increments crossing the recommended cut-off compared in a simulation model focusing on false positive signals and tumour detection time. Clin. Chim. Acta 431, 192–197 (2014).
Medline CASGoogle Scholar
18 Lund F, Petersen PH, Fraser CG et al. Calculation of limits for significant unidirectional changes in two or more serial results of a biomarker based on a computer simulation model. Ann. Clin. Biochem. 52(Pt 2), 237–244 (2014).
MedlineGoogle Scholar
19 Bast RC Jr, Klug TL, Schaetzl E et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19–9, and carcinoembryonic antigen. Am. J. Obstet. Gynecol. 149(5), 553–559 (1984).
MedlineGoogle Scholar
20 Tuxen MK, Sölétormos G, Petersen PH et al. Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer. Gynecol. Oncol. 74(1), 12–22 (1999).
Medline CASGoogle Scholar
21 Fraser CG. Biological Variation: From Principles to Practice. AACC Press, Washington, DC, USA (2001).
Google Scholar
22 Fokkema MR, Herrmann Z, Muskiet FA et al. Reference change values for brain natriuretic peptides revisited. Clin. Chem. 252(8), 1602–1603 (2006).
Google Scholar
23 Han LY, Karavasilis V, Hagen T et al. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy. Eur. J. Cancer 46(8), 1359–1364 (2010).
Medline CASGoogle Scholar
24 Skates SJ. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials. Int. J. Gynecol. Cancer 22(Suppl. 1), S24–S26 (2012).
MedlineGoogle Scholar

Vol. 9, No. 9

Metrics

Downloaded 98 times

History

Published online 6 July 2015

Published in print September 2015

Information

Keywords

Financial & competing interests disclosure

The authors would like to thank North Zealand Hospital, Helen Rudes Fond and Olga Bryde Nielsen's Fond for financial support. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

PDF download